Condition: Advanced Solid Tumour · Sponsor: Nanjing Leads Biolabs Co.,Ltd
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
This description comes directly from the study's public registry record.
Lin Shen · 010-88121122 · doctorshenlin@sina.cn
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| AnYang Tumor Hospital | Anyang, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Henan University of Science & Technology | Luoyang, Henan, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Recruiting |
| Suining Central Hospital | Suining, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07331155